Profusa Stock

profusa.comHealthcare / BioTech & PharmaFounded: 2009Funding to Date: $60.95MM

Profusa is a developer of real-time biosensors designed to provide unprecedented insights into our overall health status.

Register To Buy and Sell Shares

For more details on financing and valuation for Profusa, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Profusa’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Profusa.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.


Management Team

William McMillan
Co-Founder, President and Chief Scientific Officer
Bruce Smith
Chief of Staff
Natalie Wisniewski Ph.D
Co-Founder, Board Member & Chief Technology Officer
Soya Gamsey Ph.D
Vice President, Chemistry Development
Kerstin Rebrin
Vice President, Medical Affairs & Clinical Development
Ben Hwang Ph.D
Chairman & Chief Executive Officer
Bradley Rice Ph.D
Vice President, Engineering R&D

Board Members

Karen Liu Ph.D
3E Bioventures Capital
Tom Gutshall
Ben Hwang Ph.D
William Frist MD
Joan Braddi

Frequently Asked Questions About Profusa’s Stock

Can you buy Profusa’s stock?
Profusa is not publicly traded on NYSE or NASDAQ in the U.S. To buy Profusa’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell Profusa’s stock?
Yes, you can sell stock of a private company like Profusa. Forge can help you sell your Profusa stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is Profusa’s stock price?
Profusa is a privately held company and therefore does not have a public stock price. However, you may access Profusa’s private market stock price with Forge Data.
What is Profusa’s stock ticker symbol?
Profusa does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Sidley Represents Profusa, Inc. in Merger with SPAC NorthView Acquisition Corp.
Profusa, a digital health company, is set to merge with NorthView Acquisition Corp, a publicly traded special purpose acquisition company (SPAC), as per a definitive business combination agreement. The merger will see Profusa become a publicly listed company. Profusa's technology allows for the constant transmission of wireless and cloud-based medical grade data for individual, professional and medical use.
Herself Health, providing primary care to women 65 and over, raises $26M
Herself Health, a healthcare provider focused on women aged 65 and over, has raised $26 million in a series A funding round led by Michael Cline of Accretive. The company, founded by Kristen Helton formerly of Amazon Care, operates a clinic in St. Paul, Minnesota where it offers a holistic approach to care. Herself Health plans to use the funding to expand its services and open more clinics.
Updated on: Jun 15, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.